Friday, September 4, 2026

Avista Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Avista Corporation And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. SMART Global Holdings, Inc.

47.9% sales growth and 5.74% return on equity

SMART Global Holdings, Inc. designs and manufactures electronic products focused in memory and computing technology areas.

SMART Global Holdings, Inc.'s sales growth this year is anticipated to be 29.3% and 22.2% for next year.

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 1.17B for the twelve trailing months.

SMART Global Holdings, Inc.'s sales growth for the next quarter is 47.9%. The company's growth estimates for the current quarter and the next is 55.7% and 50%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.74%.

Volatility

SMART Global Holdings, Inc.'s last day, last week, and last month's current volatility was 0.11%, 1.42%, and 2.55%, respectively.

SMART Global Holdings, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.15% (day), 4.31% (last week), and 4.80% (last month), respectively.

SMART Global Holdings, Inc.'s Stock Yearly Top and Bottom Value

SMART Global Holdings, Inc.'s stock is valued at $56.59 at 08:22 EST, under its 52-week high of $57.69 and way higher than its 52-week low of $20.66.

SMART Global Holdings, Inc.'s Moving Average

SMART Global Holdings, Inc.'s worth is way above its 50-day moving average of $47.91 and way higher than its 200-day moving average of $37.58.

3. eXp World Holdings, Inc.

101.4% sales growth and 31.83% return on equity

eXp World Holdings, Inc. provides cloud-based real estate brokerage services for residential homeowners and homebuyers in the United States, Canada, the United Kingdom, and Australia.

eXp World Holdings, Inc.'s sales growth this year is expected to be 54.9% and 27.2% for next year.

Year-on-year quarterly revenue growth grew by 122.4%, now sitting on 1.8B for the twelve trailing months.

eXp World Holdings, Inc.'s sales growth is a negative 0% for the current quarter and 101.4% for the next. The company's growth estimates for the current quarter and the next is a negative 0% and 140%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.83%.

Volatility

eXp World Holdings, Inc.'s last day, last week, and last month's current volatility was 4.98%, 3.98%, and 4.59%, respectively.

eXp World Holdings, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 8.70% (day), 6.76% (last week), and 7.93% (last month), respectively.

eXp World Holdings, Inc.'s Stock Yearly Top and Bottom Value

eXp World Holdings, Inc.'s stock is valued at $33.80 at 08:22 EST, way below its 52-week high of $90.00 and way above its 52-week low of $4.03.

eXp World Holdings, Inc.'s Moving Average

eXp World Holdings, Inc.'s worth is way below its 50-day moving average of $45.41 and way under its 200-day moving average of $40.33.

4. ACM Research, Inc.

35.4% sales growth and 11.86% return on equity

ACM Research, Inc., together with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide.

ACM Research, Inc.'s sales growth this year is anticipated to be 41.9% and 34.5% for next year.

Year-on-year quarterly revenue growth grew by 85.2%, now sitting on 156.62M for the twelve trailing months.

ACM Research, Inc.'s sales growth for the next quarter is 35.4%. The company's growth estimates for the current quarter and the next is 81.8% and 6.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.86%.

Volatility

ACM Research, Inc.'s last day, last week, and last month's current volatility was 2.16%, 2.44%, and 2.96%, respectively.

ACM Research, Inc.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.86% (day), 5.26% (last week), and 6.21% (last month), respectively.

ACM Research, Inc.'s Stock Yearly Top and Bottom Value

ACM Research, Inc.'s stock is valued at $73.51 at 08:22 EST, way below its 52-week high of $144.81 and way above its 52-week low of $31.61.

ACM Research, Inc.'s Moving Average

ACM Research, Inc.'s value is way below its 50-day moving average of $97.49 and way below its 200-day moving average of $86.52.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com